XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.2

Revenue (Tables)

6 Months Ended

Jun. 30, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Revenue by Sales Category

The following tables provide detail by sales category:

						Three Months Ended June 30, 2025																		Three Months Ended June 30, 2024
(in millions)						U.S.						Int’l						Total						U.S.						Int’l						Total
Established Pharmaceutical Products —
Key Emerging Markets						$	—					$	1,059					$	1,059					$	—					$	988					$	988
Other						—						324						324						—						306						306
Total						—						1,383						1,383						—						1,294						1,294
Nutritional Products —
Pediatric Nutritionals						587						467						1,054						564						495						1,059
Adult Nutritionals						370						788						1,158						369						722						1,091
Total						957						1,255						2,212						933						1,217						2,150
Diagnostic Products —
Core Laboratory						351						1,007						1,358						327						1,002						1,329
Molecular						35						88						123						33						94						127
Point of Care						104						44						148						107						49						156
Rapid Diagnostics						321						223						544						345						238						583
Total						811						1,362						2,173						812						1,383						2,195
Medical Devices —
Rhythm Management						340						333						673						292						315						607
Electrophysiology						322						378						700						287						340						627
Heart Failure						282						86						368						244						77						321
Vascular						283						474						757						275						449						724
Structural Heart						289						347						636						258						306						564
Neuromodulation						193						61						254						192						51						243
Diabetes Care						794						1,187						1,981						637						1,011						1,648
Total						2,503						2,866						5,369						2,185						2,549						4,734
Other						5						—						5						4						—						4
Total						$	4,276					$	6,866					$	11,142					$	3,934					$	6,443					$	10,377

						Six Months Ended June 30, 2025																		Six Months Ended June 30, 2024
(in millions)						U.S.						Int’l						Total						U.S.						Int’l						Total
Established Pharmaceutical Products —
Key Emerging Markets						$	—					$	2,024					$	2,024					$	—					$	1,916					$	1,916
Other						—						619						619						—						604						604
Total						—						2,643						2,643						—						2,520						2,520
Nutritional Products —
Pediatric Nutritionals						1,175						920						2,095						1,078						990						2,068
Adult Nutritionals						737						1,526						2,263						733						1,417						2,150
Total						1,912						2,446						4,358						1,811						2,407						4,218
Diagnostic Products —
Core Laboratory						683						1,852						2,535						637						1,897						2,534
Molecular						75						170						245						75						181						256
Point of Care						204						86						290						205						90						295
Rapid Diagnostics						720						437						1,157						826						498						1,324
Total						1,682						2,545						4,227						1,743						2,666						4,409
Medical Devices —
Rhythm Management						644						614						1,258						563						606						1,169
Electrophysiology						621						708						1,329						556						658						1,214
Heart Failure						544						163						707						481						145						626
Vascular						551						916						1,467						529						884						1,413
Structural Heart						571						642						1,213						491						588						1,079
Neuromodulation						369						113						482						373						96						469
Diabetes Care						1,542						2,266						3,808						1,226						1,991						3,217
Total						4,842						5,422						10,264						4,219						4,968						9,187
Other						8						—						8						7						—						7
Total						$	8,444					$	13,056					$	21,500					$	7,780					$	12,561					$	20,341

Schedule of Changes in Contract Liabilities

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2024						$	568
Unearned revenue from cash received during the period						252
Revenue recognized related to contract liability balance						(192)
Balance at June 30, 2025						$	628

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration